Q/C TECHNOLOGIES, INC. (QCLS)
Q/C Technologies, Inc. focuses its efforts on pioneering advanced quantum-class photonic computing and developing robust blockchain infrastructure. The company possesses the sole worldwide rights to LightSolver's revolutionary Light-speed Laser Processing Unit (LPU). This innovative optical and laser-driven computing system is engineered specifically for applications within the cryptocurrency sector, offering a substantial energy efficiency improvement of up to 90% while simultaneously outperforming both conventional GPUs and even quantum computing systems.
Sector: In Vitro & In Vivo Diagnostic Substances
Industry: Computer Hardware
Q/C Technologies, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 8.19M shares outstanding
USQ/C Technologies, Inc. focuses its efforts on pioneering advanced quantum-class photonic computing and developing robust blockchain infrastructure.
The company possesses the sole worldwide rights to LightSolver's revolutionary Light-speed Laser Processing Unit (LPU). This innovative optical and laser-driven computing system is engineered specifically for applications within the cryptocurrency sector, offering a substantial energy efficiency improvement of up to 90% while simultaneously outperforming both conventional GPUs and even quantum computing systems.
Leadership
Mitchell Glass
Chief Medical Officer & Director
Ian Thomas Rhodes
Chief Financial Officer
Joshua N. Silverman
Executive Chairman of the Board
Robert Schatz
Investor Relations Officer
Employees
3
Country
US
Sector
Technology
Website
qctechnologies.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Silverman Joshua | Executive Chairman | Grant/Award | 77.4K | -- | Oct 1, 2026 |
| Silverman Joshua | Executive Chairman | Grant/Award | 16.6K | -- | Jul 10, 2026 |
 Bernstein Bruce | Director | Grant/Award | 50.0K | -- | Apr 13, 2026 |
 Glass Mitchell | Chief Medical Officer | Grant/Award | 50.0K | -- | Apr 13, 2026 |
 Voss Chelsea Sierra | Director | Grant/Award | 50.0K | -- | Apr 13, 2026 |
 Friscia Stephen | Director | Grant/Award | 50.0K | -- | Apr 13, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
PharmaCyte Biotech, Inc. · may incl. warrants· filed Nov 2025 | 8.5M | 74.0% as filed | 13D |
 Voss Chelsea Sierra Director | 239.9K | 2.9% | FORM 4 |
 Silverman Joshua Executive Chairman, Director | 210.8K | 2.6% | FORM 4 |
Quinn Opportunity Partners LLC | 123.0K | 1.5% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 115.0K | 1.4% | 13F |
JANE STREET GROUP, LLC | 87.2K | 1.1% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 70.7K | 0.9% | 13F |
UBS Group AG | 58.9K | 0.7% | 13F |
BALYASNY ASSET MANAGEMENT L.P. | 57.7K | 0.7% | 13F |
HRT FINANCIAL LP | 50.4K | 0.6% | 13F |
Insiders
- Silverman JoshuaExecutive Chairman
- Bernstein BruceDirector
- Glass MitchellChief Medical Officer
- Voss Chelsea SierraDirector
- Friscia StephenDirector
- White Billy JoeDirector
- RAUCH GARY M
- PharmaCyte Biotech, Inc.10% Owner
based on 8.19M shares outstanding
US30d Avg
658.26K
60d Avg
7.68M
90d Avg
5.05M